Authors
Latest:
Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?Four pharmacists offer advice for clinics on how to prepare for new self-administered biosimilar products, including adalimumab biosimilars, and overcome emerging administrative challenges.
Latest:
The Top 5 Biosimilar Articles for the Week of September 11Here are the top 5 biosimilar articles for the week of September 11, 2023.
Latest:
Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?Four pharmacists offer advice for clinics on how to prepare for new self-administered biosimilar products, including adalimumab biosimilars, and overcome emerging administrative challenges.
Latest:
Contributor: What Is the Value of the Interchangeability Designation for a Biosimilar?If every adalimumab biosimilar had an interchangeability designation, the United States could save additional $765 million annually, according to calculations from 3 biosimilar experts.
Latest:
Dr Fran Gregory Discusses the Unique Requirements for Handling BiosimilarsFran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses how specialty pharmacists manage inventory, storage, and handling of biosimilars.
Latest:
Column: India Struggles to Meet International Biologics StandardsAn internationally recognized authority on biosimilar development discusses varieties of copy biologics in India and the need to distinguish these from true biosimilars.
Latest:
Contributor: What Is the Value of the Interchangeability Designation for a Biosimilar?If every adalimumab biosimilar had an interchangeability designation, the United States could save additional $765 million annually, according to calculations from 3 biosimilar experts.
Latest:
Opinion: Biosimilars Offer Savings and Access for US PatientsIn this column, officials from the Biosimilars Forum and Xcenda discuss how biosimilar competition has lowered prices of originator biologics and improved patient access.
Latest:
Biosimilars and Women's Health: Realizing the PotentialThe potential and promise of biosimilars are there—it is up to all of us to bring it to reality so we can expand access to safe, effective, affordable drugs for women.
Latest:
Opinion: Support Health Equity and Access to Health Care With More Affordable Treatment OptionsChanges in federal and state policy can help liberate the savings potential in biosimilars and broaden investment in our health care system.
Latest:
Contributor: The Trouble With IP for Digital Health and Precision MedicineTwo experts in biosimilar intellectual property (IP) law break down the issues that digital health and precision medicine face with IP and the history of case law that has created the current landscape.
Latest:
Dr Chelsee Jensen Speaks on How Health Systems Can Build Confidence in BiosimilarsChelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, explains what health organizations and health systems can do to better manage and instill confidence in biosimilars.
Latest:
Most Israeli Gastroenterologists Prefer Reference Products Over BiosimilarsAlthough 75% of gastroenterologists believed that the efficacy of biosimilars and biologics were the same, most clinicians still preferred the brand name drug option.
Latest:
Oncological Biosimilars Shown to Be as Safe as Their Reference ProductsStudy finds patients with cancer feel reassured that biosimilars provide a safe, adequate, and cost-effective alternative to the pricier reference drug.
Latest:
What We Learned About Biologics on Summer VacationIntellectual property law attorneys from the Washington, DC, offices of McDermott Will & Emery LLP, discuss 5 of the most significant trends in biologics litigation that have emerged in recent months.
Latest:
Opinion: Embrace the Era of Next-Generation BiologicsBincy P. Abraham, MD, explains that even when payers allow coverage for biosimilars, providers may still be hesitant to use them.
Latest:
Opinion: Efforts to Improve Biosimilars Education Are a Start, but Payer Policies Must Catch UpDespite improvements in biosimilar education efforts for future health care professionals, payer policies need a major revamp to ensure that biosimilar use is encouraged, according to Pfizer's Mike Gladstone.
Latest:
Making Patients in Canada Switch to Etanercept Biosimilars Caused No Harm or Changes in Health Care Use, Study FindsHealth Canada approved biosimilars Brenzys and Erelzi in August 2016 and April 2017, respectively. The study tracked effects of the first phase of the British Columbia Ministry of Health’s Biosimilar Initiative, which required patients to switch to biosimilars starting in May 2019.
Latest:
Contributor: The Biosimilars Wave Is Crashing on the Shores of Biopharma DevelopmentSt John Skilton, PhD, vice president of product strategy and marketing at Protein Metrics, takes a deep dive into how the development of biosimilars is evolving and how tools, such as mass spectrometry, can help companies keep up with advancing technology.
Latest:
Pharmacy Can Help Drive Adoption of Rheumatoid Arthritis BiosimilarsPharmacists will have the opportunity to use their knowledge of biosimilars to reinforce their benefits, safety, and efficacy.
Latest:
Contributor: What Is the Value of the Interchangeability Designation for a Biosimilar?If every adalimumab biosimilar had an interchangeability designation, the United States could save additional $765 million annually, according to calculations from 3 biosimilar experts.
Latest:
Contributor: The Trouble With IP for Digital Health and Precision MedicineTwo experts in biosimilar intellectual property (IP) law break down the issues that digital health and precision medicine face with IP and the history of case law that has created the current landscape.
Latest:
Americans Say Drug Costs Are Too High, and They Are RightThe executive director of the Biosimilars Forum calls for policies to support adoption of lower-cost biologics.
Latest:
Why Are Companies Launching Biosimilars With 2 Prices? Julie Reed ExplainsWhy are companies pricing their adalimumab biosimilars with 2 prices? Can the United States expect more of this pricing strategy for future biosimilar launches? Julie Reed, executive director of the Biosimilars Forum, has the answers.
Latest:
Opinion: Purple Book Patent Listings Are Only a First StepIntellectual property attorneys from Axinn discuss the limitations of the Purple Book patent disclosure requirements and the burden these impose on biosimilar developers.
Latest:
Opinion: The Inflation Reduction Act is a Step Backward for Biosimilar CompetitionIn response to another opinion piece, Craig Burton, from the Association for Accessible Medicines, argued that the Inflation Reduction Act of 2022 could prevent biosimilar competition, and lower drug prices as a result.
